SCHEMBL474055

SCHEMBL474055

CCOC(=O)c1ccc(Cl)nc1C(F)(F)F

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.57
NPSR1 Q6W5P4 1/20 0.51
IDO1 P14902 1/20 0.49
XPO1 O14980 1/20 0.48
MAPT P10636 1/20 0.46
TSHR P16473 2/20 0.45
NFKB1 P19838 3/20 0.44
ATF1 P18846 1/20 0.44
JUN P05412 2/20 0.44
NFKB2 Q00653 2/20 0.44
RELA Q04206 2/20 0.44
ALDH1A1 P00352 3/20 0.43
HPGD P15428 1/20 0.42
HDAC3 O15379 1/20 0.42
HDAC4 P56524 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6377043 0.88 KDM4E (0.59) KDM4ENPSR1IDO1MAPTTSHR
SCHEMBL15567052 0.85 KDM4E (0.64) KDM4ENPSR1IDO1MAPTTSHR
SCHEMBL2816156 0.84 KDM4E (0.46) KDM4ENPSR1IDO1XPO1MAPT
SCHEMBL122615 0.84 KDM4E (0.51) KDM4ENPSR1IDO1XPO1MAPT
SCHEMBL5077233 0.84 KDM4E (0.58) KDM4ENPSR1IDO1MAPTTSHR
SCHEMBL4192553 0.84 KDM4E (0.58) KDM4ENPSR1IDO1MAPTTSHR
SCHEMBL30751960 0.83 XPO1 (0.55) KDM4EXPO1MAPTNFKB1ATF1
SCHEMBL28830749 0.83 XPO1 (0.55) KDM4EXPO1MAPTNFKB1ATF1
SCHEMBL6380407 0.81 KDM4E (0.56) KDM4ENPSR1IDO1MAPTTSHR
SCHEMBL6375898 0.80 KDM4E (0.54) KDM4ENPSR1IDO1MAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4719394-A2 INHIBITORS OF TYK2 Atomwise Inc. (US) 2026-04-08 EP disclosed
US-20260048051-A1 TREATMENT OF INFLAMMATORY BOWEL DISEASE ATOMWISE INC (US) 2026-02-19 US disclosed
US-20250375432-A1 COMPOUNDS THAT MODULATES AMPA RECEPTOR FUNCTION UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2025-12-11 US disclosed
US-12383540-B2 Compounds that modulates AMPA receptor function UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2025-08-12 US disclosed
US-12358904-B2 Inhibitors of TYK2 Atomwise Inc. (US) 2025-07-15 US disclosed
US-20240417396-A1 INHIBITORS OF TYK2 Atomwise Inc. 2024-12-19 US disclosed
WO-2024250010-A2 INHIBITORS OF TYK2 Atomwise Inc. (US) 2024-12-05 WO disclosed
EP-3759092-B1 COMPOUNDS THAT MODULATES AMPA RECEPTOR FUNCTION UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) 2023-12-20 EP disclosed
US-20230382893-A1 AMIDE DERIVATIVE HAVING ANTIVIRAL ACTIVITY SHIONOGI & CO., LTD. (JP) 2023-11-30 US disclosed
US-20230382893-A1 AMIDE DERIVATIVE HAVING ANTIVIRAL ACTIVITY SHIONOGI & CO., LTD. (JP) 2023-11-30 US disclosed
EP-1565442-A1 PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2005-08-24 EP disclosed
WO-2005074939-A1 COMBINATION OF CB2 MODULATORS AND PDE4 INHIBITORS FOR USE IN MEDICINE GLAXO GROUP LIMITED (GB) 2005-08-18 WO disclosed
EP-1562907-A1 PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2005-08-17 EP disclosed
EP-1114030-B1 PYRIDINE KETONES USEFUL AS HERBICIDES SYNGENTA PARTICIPATIONS AG (CH) 2005-06-01 EP disclosed
WO-2004029026-A1 PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2004-04-08 WO disclosed
WO-2004029027-A1 PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2004-04-08 WO disclosed
US-6498125-B2 Pyridine ketones useful as herbicides SYNGENTA PARTICIPATIONS AG (CH) 2002-12-24 US disclosed
US-20020016345-A1 Pyridine ketones useful as herbicides SYNGENTA PARTICIPATIONS AG (CH) 2002-02-07 US disclosed
EP-1114030-A1 PYRIDINE KETONES USEFUL AS HERBICIDES Syngenta Participations AG (CH) 2001-07-11 EP disclosed
WO-2000015615-A1 PYRIDINE KETONES USEFUL AS HERBICIDES SYNGENTA PARTICIPATIONS AG (CH) 2000-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250375432-A1 COMPOUNDS THAT MODULATES AMPA RECEPTOR FUNCTION GRIN1, GRM1, GRIN2A KDM4E 3318/4885NPSR1 79/4885IDO1 2161/4885
US-20240417396-A1 INHIBITORS OF TYK2 TYK2, LCK, JAK2 KDM4E 302/4885NPSR1 3566/4885IDO1 170/4885
US-20260048051-A1 TREATMENT OF INFLAMMATORY BOWEL DISEASE TYK2, FRK, DYRK2 KDM4E 642/4885NPSR1 3246/4885IDO1 144/4885
US-20230382893-A1 AMIDE DERIVATIVE HAVING ANTIVIRAL ACTIVITY ZC3HAV1, ZC3HAV1L, IFNAR1 KDM4E 618/4885NPSR1 1924/4885IDO1 704/4885
US-12358904-B2 Inhibitors of TYK2 TYK2, LCK, JAK2 KDM4E 302/4885NPSR1 3566/4885IDO1 170/4885
US-12383540-B2 Compounds that modulates AMPA receptor function GRIN1, GRM1, GRIN2A KDM4E 3845/4885NPSR1 78/4885IDO1 1714/4885
US-20020016345-A1 Pyridine ketones useful as herbicides DDT, PDHA1, IDH2 KDM4E 461/4885NPSR1 2031/4885IDO1 660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.